Browsing Tag
taldefgrobep alfa
1 post
Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology
Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026.